

# **Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study**

## **AUTHORS**

Alex F. Herrera<sup>1</sup>, Manish R. Patel<sup>2</sup>, John M. Burke<sup>3</sup>, Ranjana Advani<sup>4</sup>, Bruce D. Cheson<sup>5,6</sup>, Jeff P. Sharman<sup>7</sup>, Elicia Penuel<sup>8</sup>, Andrew G. Polson<sup>8</sup>, Chen Di Liao<sup>9</sup>, Chunze Li<sup>8</sup>, Eva Schuth<sup>8</sup>, Anjali Vaze<sup>8</sup>, Divya Samineni<sup>8</sup>, Rebecca Elstrom<sup>8,10</sup>, James Cooper,<sup>8</sup> Catherine Diefenbach<sup>11</sup>

## **Supplementary Data**

**Supplementary Table S1.** Adverse events regardless of attribution to study drug in  $\geq 10\%$  patients overall

MedDRA preferred term	DCDS0780A <2.4 mg/kg monotherapy (n=11)	DCDS0780A $\geq 2.4$ mg/kg monotherapy (n=40)	DCDS0780A $\geq 3.6$ mg/kg + rituximab (n=9)	All patients (N=60)
<b>Patients with <math>\geq 1</math> AE, n (%)</b>	11 (100)	40 (100)	9 (100)	60 (100)
<b>Total no. events</b>	<b>93</b>	<b>369</b>	<b>84</b>	<b>546</b>
Fatigue	4 (36)	20 (50)	3 (33)	27 (45)
Vision blurred	0	18 (45)	5 (56)	23 (38)
Nausea	4 (36)	16 (40)	2 (22)	22 (37)
Diarrhea	2 (18)	13 (33)	4 (44)	19 (32)
Corneal deposits	1 (9)	14 (35)	2 (22)	17 (28)
Abdominal pain	3 (27)	10 (25)	3 (33)	16 (27)
Neutropenia	2 (18)	14 (35)	0	16 (27)
Neuropathy peripheral	1 (9)	9 (23)	4 (44)	14 (23)
Decreased appetite	2 (18)	7 (18)	2 (22)	11 (18)
Cough	1 (9)	7 (18)	1 (11)	9 (15)
Dizziness	1 (9)	5 (13)	3 (33)	9 (15)
Headache	5 (45)	3 (8)	1 (11)	9 (15)
Peripheral sensory neuropathy	2 (18)	5 (13)	1 (11)	8 (13)
Pyrexia	0	6 (15)	2 (22)	8 (13)
Vomiting	1 (9)	5 (13)	2 (22)	8 (13)
Gastroesophageal reflux disease	1 (9)	3 (8)	2 (22)	6 (10)
Keratitis	0	3 (8)	3 (33)	6 (10)
Nasal congestion	0	5 (13)	1 (11)	6 (10)
Pruritus	2 (18)	4 (10)	0	6 (10)
Thrombocytopenia	0	6 (15)	0	6 (10)
Weight decreased	2 (18)	3 (8)	1 (11)	6 (10)

**Supplementary Table S2.** Summary of toxicities under the basket term for peripheral neuropathy, pulmonary toxicities, and hepatic toxicities

	<b>DCDS0780A &lt;2.4 mg/kg monotherapy (n=11)</b>	<b>DCDS0780A ≥2.4 mg/kg monotherapy (n=40)</b>	<b>DCDS0780A ≥3.6 mg/kg + rituximab (n=9)</b>	<b>All patients (N=60)</b>
<b>Peripheral neuropathy</b>				
Patients with ≥1 AE, n (%)	6 (55)	16 (40)	6 (67)	28 (47)
<b>Total no. of events</b>	<b>6</b>	<b>23</b>	<b>7</b>	<b>36</b>
Neuropathy peripheral	1 (9)	9 (23)	4 (44)	14 (23)
Peripheral sensory neuropathy	2 (18)	5 (13)	1 (11)	8 (13)
Muscular weakness	1 (9)	4 (10)	0	5 (8)
Gait disturbance	0	1 (3)	1 (11)	2 (3)
Paresthesia	1 (9)	1 (3)	0	2 (3)
Peripheral motor neuropathy	0	1 (3)	1 (11)	2 (3)
Burning sensation	1 (9)	0	0	1 (2)
<b>Pulmonary</b>				
Patients with ≥1 AE, n (%)	5 (45)	15 (38)	3	23 (38)
<b>Total no. of events</b>	<b>6</b>	<b>25</b>	<b>5</b>	<b>36</b>
Cough	1 (9)	7 (18)	1 (11)	9 (15)
Dyspnea	1 (9)	3 (8)	0	4 (7)
Dyspnea exertional	1 (9)	2 (5)	1 (11)	4 (7)
Pneumonia	0	4 (10)	0	4 (7)
Pneumonitis	0	2 (5)	1 (11)	3 (5)
Pleural effusion	0	2 (5)	0	2 (3)
Productive cough	1 (9)	0	1 (11)	2 (3)
Acute respiratory distress syndrome	0	1 (3)	0	1 (2)
Chest pain	1 (9)	0	0	1 (2)
Lung infiltration	0	1 (3)	0	1 (2)
Pleuritic pain	1 (9)	0	0	1 (2)
Pulmonary embolism	0	1 (3)	0	1 (2)
Tachypnea	0	1 (3)	0	1 (2)
<b>Hepatic</b>				
Patients with ≥1 AE, n (%)	1 (9)	3 (8)	1 (11)	5 (8)
<b>Total no. of events</b>	<b>1</b>	<b>6</b>	<b>4</b>	<b>11</b>
Alanine aminotransferase increased	0	3 (8)	1 (11)	4 (7)

Aspartate aminotransferase increased	0	3 (8)	1 (11)	4 (7)
Blood alkaline phosphatase increased	1 (9)	0	1 (11)	2 (3)

**Supplementary Table S3.** Summary of ocular toxicities related to study treatment

	<b>DCDS0780A &lt;2.4 mg/kg monotherapy (n=11)</b>	<b>DCDS0780A ≥2.4 mg/kg monotherapy (n=40)</b>	<b>DCDS0780A ≥3.6 mg/kg + rituximab (n=9)</b>	<b>All patients (N=60)</b>
<b>OCULAR</b>				
Patients with ≥1 AE, <i>n</i> (%)	1 (9)	21 (53)	6 (67)	28 (47)
<b>Total no. of events</b>	<b>4</b>	<b>49</b>	<b>13</b>	<b>66</b>
Vision blurred	0	16 (40)	5 (56)	21 (35)
Corneal deposits	1 (9)	14 (35)	2 (22)	17 (28)
Keratitis	0	3 (8)	3 (33)	6 (10)
Dry eye	1 (9)	2 (5)	1 (11)	4 (7)
Cataract	0	2 (5)	0	2 (3)
Asthenopia	0	1 (3)	0	1 (2)
Corneal opacity	0	1 (3)	0	1 (2)
Corneal thickening	1 (9)	0	0	1 (2)
Eye discharge	0	1 (3)	0	1 (2)
Eye irritation	0	1 (3)	0	1 (2)
Ocular discomfort	0	1 (3)	0	1 (2)
Punctate keratitis	1 (9)	0	0	1 (2)

**Supplementary Table S4.** Pharmacokinetic parameters for DCDS0780A ± rituximab (R)

	<b>0.3 mg/kg (n=3)</b>	<b>0.6 mg/kg (n=3)</b>	<b>1.2 mg/kg (n=5)</b>	<b>2.4 mg/kg (n=10)</b>	<b>3.6 mg/kg (n=17)</b>	<b>3.6 mg/kg + R (n=3)</b>	<b>4.8 mg/kg (n=13)</b>	<b>4.8 mg/kg + R (n=6)</b>
<b>Total Antibody</b>								
t <sub>1/2</sub> (day)	5.36 (85.6)	7.32 (48.9)	9.75 (55.1)	8.79 (57.3)	18.3 (82.9)	23.6 (63.2)	10.5 (51.7)	17.7 (16.5) <sup>a</sup>
C <sub>max</sub> (ug/mL)	5.92 (9.4)	13.7 (32.6)	38.4 (89.3)	41.9 (25.0)	84.3 (20.9)	80.0 (44.3)	97.8 (26.5)	86.7 (21.1)
AUC <sub>∞</sub> (day*ug/mL)	34.7 (75.6)	88.4 (83.4)	152 (67.8)	301 (52.5)	964 (47.3)	1160 (15.7)	824 (56.6)	1360 (14) <sup>a</sup>
CL (mL/day*kg)	12.4 (64.5)	10.8 (73.5)	20.2 (133.0)	14.5 (120.6)	7.22 (176.8)	3.17 (16.1)	16.4 (176.8)	3.58 (13.9) <sup>a</sup>
<b>acMMAE</b>								
t <sub>1/2</sub> (day)	6.84 (86.8)	5.81 (34.4)	8.53 (14.7)	7.43 (59.2)	11.1 (42.4)	9.68 (0.8)	8.27 (40.8)	9.71 (5.9)
C <sub>max</sub> (ng/mL)	62.7 (9.5)	197 (31.2)	229 (20.8)	456 (22.1)	824 (19.1)	786 (28.8)	898 (21.4)	810 (16.5)
AUC <sub>Inf</sub> (day*ng/mL)	341 (74.5)	797 (65.5)	1150 (68.7)	2480 (46.1)	5920 (32.5)	6400 (31.5)	5300 (48.1)	8390 (11.2) <sup>a</sup>
CL (mL/day*kg)	12.1 (59.3)	9.60 (53.1)	22.5 (105.8)	13.6 (81.4)	7.55 (80.7)	5.97 (32.9)	17.6 (141.2)	5.72 (11.1) <sup>a</sup>
<b>Unconjugated MMAE</b>								
C <sub>max</sub> (ng/mL)	0.188 (36.4)	0.634 (73.1)	1.74 (110.6)	1.80 (73.3) <sup>b</sup>	3.00 (86.2)	1.84 (47.1)	6.07 (96.5)	2.75 (52.6)
AUC <sub>last</sub> (day*ng/mL)	1.95 (21.8)	8.14 (58.9)	10.4 (65.4)	22.4 (63.2) <sup>b</sup>	34.8 (85.2)	18.9 (26.7)	50.6 (64.0)	34.0 (51.4)

<sup>a</sup>n=5; <sup>b</sup>n=6